| Unadjusted models | Fully adjusted model (N = 103) | Final model (N = 103) | ||||||
---|---|---|---|---|---|---|---|---|---|
Risk factors | B* | 95% CI | P-value | B* | 95% CI | P-value | B* | 95% CI | P- value |
RSV negative bronchiolitis | 0.335 | 0.019, 0.651 | 0.038 | 0.010 | −0.337, 0.357 | 0.957 | 0.009 | −0.336, 0.354 | 0.958 |
Male gender | −0.112 | −0.388, 0.164 | 0.423 |  |  |  |  |  |  |
Age at follow-up (months) | −0.004 | −0.277, 0.269 | 0.977 |  |  |  |  |  |  |
Height (cm) | 0.024 | 0.005, 0.043 | 0.015 | 0.025 | 0.000, 0.050 | 0.053 | 0.024 | 0.007, 0.041 | 0.006 |
Weight (kg) | 0.015 | 0.001, 0.030 | 0.058 | −0.001 | −0.021, 0.020 | 0.946 |  |  |  |
Atopy | 0.510 | 0.219, 0.802 | 0.001 | 0.269 | −0.073, 0.611 | 0.121 | 0.269 | −0.071, 0.609 | 0.120 |
Current asthma | −0.033 | −0.366 ,0.299 | 0.977 |  |  |  |  |  |  |
Ln DRS | 0.061 | −0.025, 0.148 | 0.161 | 0.094 | 0.015, 0.173 | 0.020 | 0.094 | 0.017, 0.172 | 0.018 |
FEV1% | 0.015 | 0.000, 0.029 | 0.044 | 0.018 | 0.004, 0.032 | 0.013 | 0.018 | 0.004, 0.031 | 0.012 |
FEF25–75% | 0.002 | −0.005, 0.008 | 0.610 |  |  |  |  |  |  |
Use of inhaled steroids preceding 12 months | 0.003 | −0.494, 0.488 | 0.990 |  |  |  |  |  |  |
Interaction | Â | Â | Â | Â | Â | Â | Â | Â | Â |
RSV negative bronchiolitis × atopy |  |  |  | 0.736 | 0.125, 1.346 | 0.019 | 0.736 | 0.128, 1.343 | 0.018 |